
    
      A multi-centre, randomized, placebo and active-controlled, 6-week study of inhaled TPI 1020,
      inhaled budesonide or matching placebo (random allocation of eligible patients to the three
      treatments at a ratio of 3:3:1), to evaluate the safety, tolerability and pharmacodynamic
      activity of TPI 1020 in 42 evaluable COPD subjects.
    
  